Value20242025TTMSelling/general/admin expenses755.35 M731.74 M731.74 MResearch & development149.32 M172.92 M172.92 MOperating income691.08 M252.87 M252.87 MNon-Operating Income, Total49.5 M47.34 M47.34 MInterest expense, net of interest capitalized53.65 M70.27 M70.27 MNon-Operating Income, excl. Interest Expenses-36.49 M-54.38 M-54.38 MUnusual income/expense32.34 M31.45 M31.45 MPretax income705.54 M296.71 M296.71 MEquity in earnings4.23 M5.61 M5.61 MTaxes266 K51.68 M51.68 MNon-controlling/minority interest———After tax other income/expense———Net income before discontinued operations705.81 M245.03 M245.03 MDiscontinued operations———Net income705.81 M245.03 M245.03 MDilution adjustment81.04 M00Preferred dividends40.52 M00Diluted net income available to common stockholders746.33 M245.03 M245.03 MBasic earnings per share (Basic EPS)-6.23-1.41-1.41Diluted earnings per share (Diluted EPS)-6.23-1.41-1.41Average basic shares outstanding119.85 K174.26 K693.1 KDiluted shares outstanding119.85 K174.26 K693.1 KEBITDA-210.09 M369.89 M369.47 MEBIT-238.34 M333.26 M332.85 MCost of revenue13.97 M15.15 M15.15 MOther cost of goods sold———Depreciation & amortization (cash flow)28.25 M36.63 M36.63 M
Tempus AI, Inc. Class A
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."